Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Tafluprost: a novel prostaglandin analog for treatment of glaucoma.

Pantcheva MB, Seibold LK, Awadallah NS, Kahook MY.

Adv Ther. 2011 Sep;28(9):707-15. doi: 10.1007/s12325-011-0055-8. Epub 2011 Aug 18. Review.

PMID:
21858491
2.

IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.

Hommer A, Mohammed Ramez O, Burchert M, Kimmich F.

Curr Med Res Opin. 2010 Aug;26(8):1905-13. doi: 10.1185/03007995.2010.492030.

PMID:
20553122
3.

Tafluprost: the first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension.

Swymer C, Neville MW.

Ann Pharmacother. 2012 Nov;46(11):1506-10. doi: 10.1345/aph.1R229. Epub 2012 Oct 23. Review.

PMID:
23092867
4.

Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.

Uusitalo H, Pillunat LE, Ropo A; Phase III Study Investigators.

Acta Ophthalmol. 2010 Feb;88(1):12-9. doi: 10.1111/j.1755-3768.2010.01862.x.

5.

Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma.

Lorenz K, Pfeiffer N.

Expert Opin Pharmacother. 2014 Oct;15(15):2255-62. doi: 10.1517/14656566.2014.955471. Epub 2014 Aug 29. Review. Erratum in: Expert Opin Pharmacother. 2014 Nov;15(16):2473.

PMID:
25170534
6.

Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension.

Erb C, Lanzl I, Seidova SF, Kimmich F.

Adv Ther. 2011 Jul;28(7):575-85. doi: 10.1007/s12325-011-0038-9. Epub 2011 Jun 30.

PMID:
21725844
7.

Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis.

Hamacher T, Airaksinen J, Saarela V, Liinamaa MJ, Richter U, Ropo A.

Acta Ophthalmol Suppl (Oxf ). 2008;242:14-9. doi: 10.1111/j.1755-3768.2008.01381.x.

PMID:
18752510
8.

Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.

Uusitalo H, Chen E, Pfeiffer N, Brignole-Baudouin F, Kaarniranta K, Leino M, Puska P, Palmgren E, Hamacher T, Hofmann G, Petzold G, Richter U, Riedel T, Winter M, Ropo A.

Acta Ophthalmol. 2010 May;88(3):329-36. doi: 10.1111/j.1755-3768.2010.01907.x.

9.

A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost.

Traverso CE, Ropo A, Papadia M, Uusitalo H.

J Ocul Pharmacol Ther. 2010 Feb;26(1):97-104. doi: 10.1089/jop.2009.0066.

PMID:
20148656
10.

Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence.

Kuwayama Y, Hashimoto M, Kakegawa R, Nomura A, Shimada F.

Adv Ther. 2017 Jun;34(6):1411-1425. doi: 10.1007/s12325-017-0549-0. Epub 2017 May 13.

PMID:
28502035
11.

Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients.

Rossi GC, Pasinetti GM, Raimondi M, Ricciardelli G, Scudeller L, Blini M, Amisano A, Bianchi PE.

Expert Opin Drug Saf. 2012 Jul;11(4):519-25. doi: 10.1517/14740338.2012.690734. Epub 2012 Jun 13.

PMID:
22690824
12.

Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension.

Hoy SM.

Drugs. 2015 Oct;75(15):1807-13. doi: 10.1007/s40265-015-0476-9. Review.

PMID:
26431840
13.

Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial.

Chabi A, Baranak C, Lupinacci R, Herring WJ.

Int J Clin Pract. 2016 Jul;70(7):577-86. doi: 10.1111/ijcp.12815. Epub 2016 Jun 13.

PMID:
27292765
14.

Spanish multicenter tafluprost tolerability study.

Milla E, Stirbu O, Rey A, Duch S, Buchacra O, Robles A, Navarro C, Gil R, Cordero JM.

Br J Ophthalmol. 2012 Jun;96(6):826-31. doi: 10.1136/bjophthalmol-2011-301015. Epub 2012 Mar 7.

PMID:
22399693
15.

[Efficacy and tolerability of preservative-free tafluprost 0.0015 % in the treatment of glaucoma and ocular hypertension].

Karhanová M, Mlčák P, Fryšák Z, Marešová K.

Cesk Slov Oftalmol. 2012 Oct;68(4):150-5. Czech.

PMID:
23214487
16.
17.

Tafluprost for glaucoma.

Papadia M, Bagnis A, Scotto R, Traverso CE.

Expert Opin Pharmacother. 2011 Oct;12(15):2393-401. doi: 10.1517/14656566.2011.606810. Review.

PMID:
21916788
19.

Effect of preservative-free tafluprost on keratocytes, sub-basal nerves, and endothelium: a single-blind one-year confocal study on naïve or treated glaucoma and hypertensive patients versus a control group.

Rossi GC, Blini M, Scudeller L, Ricciardelli G, Depolo L, Amisano A, Bossolesi L, Pasinetti GM, Bianchi PE.

J Ocul Pharmacol Ther. 2013 Nov;29(9):821-5. doi: 10.1089/jop.2013.0069. Epub 2013 Aug 14.

PMID:
23944905
20.

Tafluprost Ophthalmic Solution 0.0015 %: A Review in Glaucoma and Ocular Hypertension.

Keating GM.

Clin Drug Investig. 2016 Jun;36(6):499-508. doi: 10.1007/s40261-016-0413-z. Review.

PMID:
27225879

Supplemental Content

Support Center